Reason for request
Reassessment of actual benefit and improvement in actual benefit under article R-163-21 of the Social Security Code.
Clinical Benefit
| Moderate |
The actual benefit is moderate. |
Clinical Added Value
| minor |
The Transparency Committee is of the opinion that the REMODULIN range of proprietary drugs provides a minor improvement in actual benefit (IAB IV) in the treatment of idiopathic pulmonary arterial hypertension for patients in functional class III. |
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
ydJM4X1xyyLU5H9F
Listen
